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Abstract 1 
Background: This study focused on understanding the coping strategies and related 2 
behavioral changes of women who were recently diagnosed with Herpes Simplex Virus 3 
Type 2 (HSV-2). In particular, we were interested in how coping strategies, condom use, 4 
and acyclovir uptake evolve over time.   5 
Methods: Twenty-eight women screening positive for HSV-2 were recruited through a 6 
public health STD clinic and the Indianapolis Community Court. Participants completed 7 
three semi-structured interviews with a female researcher over a six-month period. The 8 
interviews focused on coping strategies for dealing with a diagnosis, frequency of 9 
condom use, suppressive and episodic acyclovir use, and the utilization of HSV-2 10 
support groups. Interview data were analyzed using content analysis to identify and 11 
interpret concepts and themes that emerged from the interviews. 12 
Results: Women employed a variety of coping strategies following an HSV-2 diagnosis. 13 
32% of women reported an increase in religious activities, 20% of women reported an 14 
increase in substance use, and 56% of women reported engaging in other coping 15 
activities. 80% of women reported abstaining from sex immediately following the 16 
diagnosis, but 76% of women reported engaging in sex again by the six-month interview. 17 
Condom and medication use did not increase and HSV-2 support groups were not 18 
utilized by participants. 19 
Conclusions: All participants reported engaging in at least one coping mechanism after 20 
receiving their diagnosis. A positive diagnosis did not seem to result in increased use of 21 
condoms for the majority of participants and the use of acyclovir was low overall. 22 
23 
Introduction 24 
Herpes Simplex Virus Type 2 (HSV-2) is an extremely common sexually transmitted 25 
infection. The age-adjusted seroprevalence rate in the United States is 17.0%, with 26 
women having a seroprevalence rate almost double that of men (men 11.2% & women 27 
23.1%).1 The majority of people infected with HSV-2 experience no symptoms and thus 28 
may be unaware of their infection, despite shedding virus and potentially transmitting 29 
HSV-2 unintentionally to their sexual partners.2 Diagnosis and treatment of HSV-2 30 
infection is important given its association with increased susceptibility to other STIs, 31 
including HIV.3-5  By expanding access to HSV-2 serological testing, community-level 32 
prevalence could be reduced, as asymptomatic individuals who know their serostatus 33 
may take measures to decrease the probability of transmission to uninfected partners 34 
through suppressive therapy, condom use and avoiding sexual contact during 35 
outbreaks.636 
 37 
Previous research indicates that condom use can reduce the transmission of HSV-2.7, 8 38 
However, the extent to which a person changes their condom use behaviors after 39 
learning of their HSV-2 diagnosis is less known. The use of daily suppressive acyclovir 40 
also reduces asymptomatic viral shedding and transmission.9-11 Acyclovir could be a 41 
useful tool in reducing HSV-2 transmission, but due to the difficulty in taking the 42 
medication regularly, it is not clear which women would be willing to use it.  43 
 44 
A diagnosis of HSV-2 can be psychologically distressing; particularly for persons who 45 
have never experienced symptoms and are unaware they are seropositive.12, 13 46 
However, severe, lasting negative emotional effects generally have not been found to 47 
be associated with an HSV-2 diagnosis.14-17 Understanding women’s coping strategies 48 
after receiving an HSV-2 diagnosis is necessary for the development of evidence-based 49 
resources for HSV-2 positive individuals. For example, HSV-2 support groups have 50 
been established in many areas in the US and may serve as a useful coping 51 
mechanism for individuals recently diagnosed with HSV-2.  52 
 53 
The purpose of this study was to better understand the coping strategies and related 54 
behavioral changes of women who were recently diagnosed with HSV-2. We were 55 
interested in how coping strategies, condom use, and acyclovir uptake evolve over time. 56 
Findings from this study will provide increased understanding about coping mechanisms 57 
used by HSV-2 positive patients and may be informative for clinicians providing care to 58 
these patients. 59 
 60 
Materials and Methods 61 
Settings 62 
From October 2009-June 2010, women screening positive for HSV-2 were recruited 63 
through two different venues: an STD clinic (Bell Flower Clinic) and the Indianapolis 64 
Community Court. Two of the most common charges among women at community court 65 
include prostitution and public intoxication. Because of the STI-risk associated with 66 
commercial sex and substance abuse, particular outreach efforts have been made to 67 
increase access to STI care for this population.18 A few women had previously 68 
experienced HSV-2 symptoms, such as blisters or itching, but the majority of women 69 
were asymptomatic prior to testing. Some women developed HSV-2 symptoms post-70 
diagnosis. 71 
 72 
Recruitment 73 
Individuals attending the STD clinic were offered an HSV-2 serology test for a $30 fee.19 74 
Female defendants from the community court were offered no-cost HSV-2 serologic 75 
testing.20 Fourteen women were enrolled from the STD clinic and fourteen were enrolled 76 
from community court. Participants recruited from both locations were given 90-day 77 
prescriptions for acyclovir and referred to their primary care physician for follow-up. 78 
 79 
Procedures 80 
Participants at both locations were female, 18 years of age or older and spoke English 81 
fluently. They completed three hour-long, face-to-face, semi-structured interviews with a 82 
female researcher. The first interview was conducted within two weeks of receiving an 83 
HSV-2 diagnosis. The second interview occurred 4-7 weeks later, and the final interview 84 
occurred approximately 6 months after diagnosis. The interviews explored how 85 
receiving an HSV-2 diagnosis affected participants’ mental health and health behaviors 86 
over time. Items were grouped into 4 key domains including: coping strategies for 87 
dealing with a diagnosis, frequency of condom use, suppressive and episodic acyclovir 88 
use, and the utilization of HSV-2 support groups. Table 1 provides a list of key domains 89 
and related exemplar items to elicit participant response. During the interviews, 90 
participants were provided basic educational information about HSV-2, including how 91 
HSV-2 is transmitted, the use of condoms and daily suppressive therapy in reducing 92 
transmission, and the management of symptoms. All participants were compensated 93 
with a $40 gift card upon completion of each interview. The institutional review board at 94 
Indiana University approved the study, and each participant provided written informed 95 
consent. 96 
 97 
Analysis 98 
We focused on changes in women’s attitudes and behaviors over time. Because 99 
interviews were individually tailored, not every participant was asked about their 100 
experience with each domain at all three time points. To conduct our analyses, we 101 
organized the transcripts in chronological order by participant and read the transcripts of 102 
each participant one-by-one, which allowed us to focus on factors related to change at 103 
the individual-level. This strategy is recommended by Saldaña for analyzing qualitative 104 
data for change over time.21 We included data from women for whom there was a 105 
response to key items in two or more of the interviews for each domain. Of the 28 106 
enrolled, 3 were excluded because they completed only one interview. 107 
 108 
Data from this study were analyzed using content analysis to identify and interpret 109 
concepts and themes that emerged from the interviews.22 This method involved multiple 110 
readings of transcripts and analytical induction via open and axial coding of data using 111 
NVivo software (version 10, Doncaster, Australia) to thematically organize transcripts. 112 
To describe the sample, descriptive analyses were conducted. To assess behavioral 113 
change over time for sexual behavior, condom use, and acyclovir use, repeated 114 
measures ANOVA was used. All quantitative analyses were conducted using SPSS 115 
statistical software (version 21, Durham, NC). 116 
 117 
Results 118 
Participants 119 
In total, 25 women completed more than one interview and were included in the 120 
analyses (15 black, 9 white, 1 American Indian). Participant ages ranged from 21-61 121 
years (median, 38 years; IQR = 33-47 years). Most participants reported engaging in 122 
sexual behaviors with male partners only (88%; n=22). Of the 13 women recruited from 123 
community court, 5 reported previous involvement in exchanging sex for money or living 124 
needs. . There were no statistically significant differences in recruitment group 125 
composition by race or age. However, women recruited from the community court were 126 
significantly more likely to be unemployed (p=.03), have lower educational attainment 127 
(p=.03), and report exchanging sex for money or living needs (p=.02).  128 
 129 
Coping Strategies for dealing with an HSV-2 diagnosis 130 
Women employed a variety of coping strategies following an HSV-2 diagnosis. Most 131 
women expressed initial shock and psychological distress. (“Oh my god, it felt like a 132 
nightmare. It was the worst day of my life.”) Women were most concerned about how 133 
they had contracted HSV-2 and that HSV-2 could not be cured. Women reported 134 
engaging in a variety of behaviors to cope with their diagnosis, including an increase in 135 
religious activities, reaching out to friends or family for support and an increase in 136 
consumption of alcohol and drugs. Below we explore each coping strategy in detail. 137 
 138 
The role of religion & spirituality 139 
For some women (32%, n=8), their diagnosis caused them to increase the frequency of 140 
prayer and religious service attendance. Participants stated that spiritual activities 141 
helped them alleviate feelings of guilt (“I went to church and felt relief. I got to clear my 142 
conscience for a little while, and I felt like that was important because I needed that.”), 143 
better understand what happened (“I just prayed about it for the most part. Sometimes I 144 
just try to get an understanding of what happened.”) and receive support (“I pray a lot, 145 
and if I miss going to church, wherever I am I stop to pray. Lord, help me deal with 146 
this.”).  147 
 148 
Information seeking, staying busy, and social support 149 
Fifty-six percent of women (n=14) reported engaging in other activities to help 150 
themselves cope with their diagnosis (“I do tasks or listen to the radio, find music that I 151 
can sing along with. If I’m at home, I find a conversation to have with my kids and forget 152 
about it.”), receive support (“I’ve got a couple of really good friends I talk to and they’re 153 
telling me life’s not over, you can still have meaningful relationships with people.”) or 154 
find out more information (“I’ve read the brochures on it and tried to get some 155 
information about how it came about, what you do to treat it, when not to have sexual 156 
intercourse and stuff like that.”)  157 
 158 
The role of substance use 159 
Nearly 20% of women mentioned an increase in alcohol and drug use following their 160 
HSV-2 diagnosis. Reports of alcohol and drug use were similar between participants 161 
recruited from community court (n=3) and the STD clinic (n=2). Participants stated the 162 
substance use helped them forget about their diagnosis (“I drink, smoke marijuana, try 163 
to forget about it.”), or feel better (“Weed, wine, whatever I feel is best at that time. More 164 
drugs, more prescriptions, NyQuil, anything to just make me sleep or make me feel 165 
better, that’s what I do.”).  166 
 167 
Coping over time 168 
Coping behaviors seemed to be more important for women at the initial interview than at 169 
the last interview, which indicates the need for coping mechanisms may decrease as 170 
time progresses and women adjust to their diagnosis. Interestingly, although women 171 
engaged in a variety of coping mechanisms, none of the participants reported an 172 
interest in attending support groups for people diagnosed with HSV-2, even though 173 
participants were given extensive information about a local group.  174 
 175 
Preventing transmission to partners: Sexual activity 176 
In addition to examining coping methods, we examined women’s sexual behavior, 177 
condom use and medication use over time. There was a significant increase in the 178 
number of women reporting sexual activity over time (F(1, 20) = 22, p≤0.01, 2=.524). 179 
The majority of women (80%; n=20) reported abstaining from sex immediately after their 180 
diagnosis. However, as time progressed, most women reinitiated sexual relationships. 181 
By the six-month interview, 76% of respondents had engaged in sexual behavior again. 182 
We use narrative data from one participant to illustrate this progression. At the first 183 
interview, one woman stated, “I’m having the trust issue, and I feel like maybe I want to 184 
[have sex], but I just can’t bring myself to right now.  I’m not on that level yet. There’s 185 
just so many things that I have to iron out before I even go there.” In an interview weeks 186 
later, she said, “We’ve not been intimate yet. We’re sticking to the dating process…sort 187 
of like starting over. We do a lot of kissing like we did when we were first dating. It’s 188 
working out.” Six months later, she reported, “Yes, we have [had sex]. In the beginning, 189 
it was rough. Now, we have become closer. There’s more communication.” This 190 
process was similar across participants. Thus, in this sample, it does not appear that 191 
there were long-term negative effects on the women’s sexual lives. 192 
 193 
Preventing transmission to partners: Condom use 194 
A few women reported an increase in condom use immediately following their diagnosis, 195 
but this change was inconsistent over time (F(1, 18) = .321, p=0.58, 2=.018). Women 196 
who reported an increase in condom use stated that their diagnosis had made them 197 
more cautious, “Now I’m very cautious about not spreading it… I make that my first 198 
priority.  I know there are still other diseases like HIV and AIDS. I don’t want to die, so 199 
it’s a must that I use condoms.” However, most women reported no change in condom 200 
use. Several were already in long-term monogamous relationships in which they did not 201 
use condoms because they suspected their partner had already contracted HSV-2 (“No, 202 
we don’t use protection. I know we should, but me and him don’t use protection ‘cause I 203 
feel it’s already too late.”). Some women stated that their sexual partners didn’t want to 204 
use condoms, even though they knew the woman had HSV-2 (“It’s complicated. They 205 
know that I have it, but they don’t want to use condoms… they act like it don’t phase 206 
them.”). Thus, patient and partner knowledge of seroprevalence status alone was not 207 
sufficient to increase condom use.  208 
 209 
Preventing transmission to partners: Acyclovir use 210 
Medication use was low overall; 13 reported initiating treatment and uptake did not 211 
increase over time (F(1, 20) = .656, p=0.43, 2=.032). Some participants reported they 212 
were not aware their prescriptions would run out after 3 months, “I felt like ya’ll should 213 
have said that after three months you’re not getting suppressive therapy anymore. I 214 
didn’t know. I’m thinking, shit, if you’re diagnosed with it, they’re gonna give it to you 215 
until you stop needing it.” In Indianapolis, the cost for a 30-day regimen of suppressive 216 
therapy (400mg twice per day) ranged from $35.88 USD to $125 USD without health 217 
insurance (personal communication with pharmacy technicians at Kroger, Marsh, CVS, 218 
Kmart and Walmart in Indianapolis, IN). Some participants reported cost to be a barrier 219 
and found it a hardship to pay for medication. For example, a participant receiving 220 
Medicaid stated, “I have a three dollar co-pay, and I don’t have three dollars, but I got to 221 
come up with something. I got to get it filled so I can start feeling better. I am willing to 222 
go through the treatment and the things I have to do to have normal living.”      223 
 224 
Others assumed that medication was only necessary for an outbreak and didn’t realize 225 
they would be shedding virus and potentially transmitting HSV-2 to sexual partners. (“I 226 
still have not went to get the medicine because I don’t feel that I really have any 227 
symptoms.”) Reportedly, this erroneous belief was validated by their primary physicians, 228 
“My doctor said just to see, and if I have another break out, she’ll put me on it, but I 229 
haven’t had one.”  Several participants also expressed resistance to taking pills two 230 
times a day every day, “I hate taking pills. I don’t want to take those pills every day.” 231 
Given the lack of financial resources to maintain a lifetime of suppressive therapy, 232 
limited physician support and the daily dosage regimen, acyclovir may not be an 233 
effective tool in preventing HSV-2 transmission, especially among asymptomatic women 234 
of low socio-economic status. 235 
 236 
Discussion 237 
Our study results suggest that an HSV-2 diagnosis results in short-term behavioral 238 
changes for many women. This study adds a unique contribution to the literature 239 
because of its 3-time-point longitudinal qualitative design that enabled an in-depth 240 
exploration of participants’ behavioral changes, including how women cope with an 241 
HSV-2 diagnosis, as well as condom and medication use. Additionally, this study 242 
provides some insight into differences between two high-risk groups, those recruited 243 
from a clinical setting and those receiving community based testing.  244 
 245 
Most women expressed initial shock and psychological distress. However, as in other 246 
studies, this distress waned over time.14, 23 A large proportion (32%) of participants 247 
increased religious activities. While further research would be needed to explore the 248 
role of religiosity post-HSV-2 diagnosis, it is possible that religious organizations could 249 
be a mechanism for engaging women in care. Women also reported an increase in the 250 
consumption of alcohol and drugs (20%). A majority of women (56%) reported engaging 251 
in other types of coping behaviors, such as talking with family and friends, writing 252 
poems, listening to music or working. Despite being given information about a local 253 
HSV-2 support group, no participants attended. This study indicates that most women 254 
engage in healthy behaviors to cope with their HSV-2 diagnosis, but some women may 255 
need additional support to refrain from negative coping mechanisms.  256 
 257 
Most participants did not report a change in condom usage following their HSV-2 258 
diagnosis. This study found that HSV-2 positive individuals in long-term partnerships 259 
may not feel the need to use condoms. In fact, some men reportedly did not want to use 260 
condoms, even when they knew their female partner was HSV-2 positive. Given the role 261 
condoms play in reducing the transmission of HSV-2, further research should be 262 
conducted to determine ways to increase condom use among HSV-2 positive 263 
individuals and their sexual partners. 264 
 265 
Medication use was low. Most participants showed little interest in taking acyclovir and 266 
felt it was only necessary for outbreaks. This belief was supported by their primary care 267 
physicians. A number of participants expressed difficulty in obtaining acyclovir due to a 268 
lack of financial resources. This set of findings indicates a need for additional education 269 
and for services that make acyclovir more accessible to high-risk populations.18, 19 270 
 271 
Our findings are limited by the fact that this was a small, exploratory study of women 272 
residing in one city in the Midwestern United States. The majority of our sample 273 
participants were low income and their experiences may not be generalizable to women 274 
from more privileged backgrounds. Research should be conducted among women 275 
recently diagnosed with HSV-2 in a private practice. Additionally, 40% of women were 276 
symptomatic. This is much higher than the literature reports (10-25%).24 Further 277 
exploration may be needed to see how symptomatic versus asymptomatic women react 278 
and the potential types of resources they may need. Furthermore, we relied on self-279 
reported experiences and behaviors provided by participants. Given the nature of face-280 
to-face interviews, social desirability reporting may have occurred. Women in this study 281 
were only followed for six-months, so it is unclear how an HSV-2 diagnosis affects 282 
women over a longer time period. However, we interviewed women at regular intervals, 283 
and even with our small sample size, we were still able to detect trends.  284 
 285 
In sum, all participants reported engaging in at least one, if not several, coping 286 
mechanisms after receiving their diagnosis, both adaptive and maladaptive. A positive 287 
diagnosis did not result in increased condom use for the majority of participants and the 288 
use of acyclovir was low overall. For this sample, additional resources would be needed 289 
to provide women with acyclovir for long-term suppressive therapy. In addition, there is 290 
a need for educational interventions regarding viral shedding, the value of condom use, 291 
and strategies to enhance adherence to suppressive medication. No participant was 292 
interested in attending an HSV-2 support group. Additional studies to identify alternative 293 
support resources for HSV-2 patients would be useful. While it may seem 294 
counterintuitive, our findings suggest partnering with church services may be one 295 
potential recruitment and service provision venue. 296 
297 
Acknowledgments: The authors would like to thank the participants, the Community 298 
Court of Indianapolis, and the Marion County Health Department for their invaluable 299 
support in conducting this study. 300 
 301 
Conflict of Interest: BVDP reports receiving consulting and honoraria, not related to 302 
this work, from BD Diagnostics, Cepheid, Melinta, Rheonix and Roche Molecular 303 
Diagnostics. 304 
 305 
Source of Funding: Funding for this study was provided by the Center for Translational 306 
Science Institute (CTSI), Indiana University Purdue University Indianapolis and NIDA 307 
T32 DA 023356.  308 
309 
References 310 
1.  Xu F, Sternberg M, Kottiri B, McQuillan G, Lee F, Nahmias A, et al. Trends in herpes simplex virus 311 
type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964‐73. 312 
2.  Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, et al. Herpes simplex virus 313 
type 2 in the United States, 1976 to 1994. New England Journal of Medicine. 1997 Oct 16;337(16):1105‐314 
11. PubMed PMID: 9329932. 315 
3.  Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ, et al. Herpes simplex virus 2 316 
infection increases HIV acquisition in men and women: systematic review and meta‐analysis of 317 
longitudinal studies. AIDS. 2006 Jan 2;20(1):73‐83. PubMed PMID: 16327322. 318 
4.  Kaul R, Nagelkerke NJ, Kimani J, Ngugi E, Bwayo JJ, Macdonald KS, et al. Prevalent herpes 319 
simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to 320 
multiple sexually transmitted infections. Journal of Infectious Diseases. 2007 Dec 1;196(11):1692‐7. 321 
PubMed PMID: 18008255. 322 
5.  Wald A, Link K, Wald A, Link K. Risk of human immunodeficiency virus infection in herpes 323 
simplex virus type 2‐seropositive persons: a meta‐analysis. Journal of Infectious Diseases. 2002 Jan 324 
1;185(1):45‐52. PubMed PMID: 11756980. 325 
6.  Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J, et al. Knowledge of partners' genital 326 
herpes protects against herpes simplex virus type 2 acquisition. Journal of Infectious Diseases. 2006 Jul 327 
1;194(1):42‐52. PubMed PMID: 16741881. 328 
7.  Wald A, Langenberg A, Krantz E, Douglas J, Handsfield H, DiCarlo R, et al. The Relationship 329 
between Condom Use and Herpes Simplex Virus Acquisition. Annals of Internal Medicine. 330 
2005;143(10):707‐13. 331 
8.  Martin E, Krantz E, Gottlieb S, Magaret A, Langenberg A, Stanberry L, et al. A Pooled Analysis of 332 
the Effect of Condoms in Preventing HSV‐2 Acquisition. Archives of Internal Medicine. 333 
2009;169(13):1233‐40. 334 
9.  Sheffield J, Hollier L, Hill J, Stuart G, Wendel G. Acyclovir Prophylaxis to Prevent Herpes Simplex 335 
Virus Recurrence at Delivery: A Systematic Review. Obstetrics & Gynecology. 2003;102(6):1396‐403. 336 
10.  Wald A, Zeh J, Barnum G, Davis L, Corey L. Suppression of Subclinical Shedding of Herpes 337 
Simplex Virus Type 2 with Acyclovir. Annals of Internal Medicine. 1996;124:8‐15. 338 
11.  Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent Genital Herpes Simplex Virus 2 339 
Shedding in Immunocompetent Women: Effect of Acyclovir Treatment. The Journal of Clinical 340 
Investigation. 1997;99(5):1092‐7. 341 
12.  Melville J, Sniffen S, Crosby R, Salazar L, Whittington W, Dithmer‐Schreck D, et al. Psychosocial 342 
impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment. Sexually 343 
Transmitted Infections. 2003 Aug;79(4):280‐5. PubMed PMID: 12902574. 344 
13.  Mark H, Nanda J, Joffe A, Roberts J, Rompalo A, Melendez J, et al. Serologic screening for herpes 345 
simplex virus among university students: a pilot study. Journal of American College Health. 346 
2008;57(3):291‐6. 347 
14.  Rosenthal S, Zimet G, Leichliter J, Stanberry L, Fife K, Tu W, et al. The psychosocial impact of 348 
serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sexually Transmitted 349 
Infections. 2006;82(2):154‐7. 350 
15.  Richards J, Scholes D, Caka S, Drolette L, Magaret A, Yarbro P, et al. HSV‐2 serologic testing in an 351 
HMO population: uptake and psychosocial sequelae. Sexually Transmitted Diseases. 2007;34(9):718‐25. 352 
16.  Ross K, Johnston C, Wald A. Herpes simplex virus type 2 serological testing and psychosocial 353 
harm: a systematic review. Sexually Transmitted Infections. 2011;87(7):594‐600. 354 
17.  Provenzale A, Evans K, Russell J, Hoory T, Mark H. Psychosocial impact of a positive HSV‐2 355 
diagnosis on adults with unrecognized HSV‐2 infection. Public Health Nursing. 2011;28(4):325‐34. 356 
18. Roth A, Fortenberry J, Van Der Pol B, Rosenberger J, Dodge B, Arno J, et al. Court‐based 357 
participatory research: collaborating with the justice system to enhance sexual health services for 358 
vulnerable women in the United States. Sexual Health. 2012;9(5):445‐52. 359 
19.  Fife K, Van Der Pol B, Roth A, Brand J, Arno J, Madlem J, et al. Implementation of routine access 360 
to herpes simplex virus type 2 antibody testing in a public health sexually transmitted disease clinic. 361 
Sexually Transmitted Diseases. 2009;36(11):724‐8. 362 
20.  Zimet G, Rosenthal S, Fortenberry J, Brady R, Tu W, Wu J, et al. Factors Predicting the 363 
Acceptance of Herpes Simplex Virus Type 2 Antibody Testing Among Adolescents and Young Adults. 364 
Sexually Transmitted Diseases. 2004;31:665‐9. 365 
21.  Saldaña J. Longitudinal Qualitative Research: Analyzing Change Through Time. Walnut Creek, CA: 366 
AltaMira Press; 2003. 212 p. 367 
22.  Corbin J, Strauss A. Basics of Qualitative Research: Techniques and Procedures. 3rd ed. Los 368 
Angeles: SAGE; 2008. 369 
23.  Melville J, Sniffen S, Crosby R, Salazar L, Whittington W, Dithmer‐Schreck D, et al. Psychosocial 370 
impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment. Sexually 371 
Transmitted Infections. 2003;79:280‐5. 372 
24.  Tronstein E, Johnston C, Meei‐Li H, Selke S, Magaret A, Warren T, et al. Genital Shedding of 373 
Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons with HSV‐2 Infection. JAMA. 374 
2011;305(14):1441‐9. 375 
376 
377 
Table 1: 
Table 1: Key Domains 
Domain Exemplar Item 
Coping strategies “How are you dealing with being diagnosed with 
herpes?” 
“If it bothers you, what do you do to help stop 
thinking about it?” 
Sexual activity “How has your diagnosis affected your intimate 
relationships?” 
“Do you feel your sex life is different now than it 
was before the diagnosis?” 
Condom use “When do you use condoms with your partner?” 
“Have you altered your condom use since this 
diagnosis?” 
Use of acyclovir “Are you planning to take medication for HSV-2?” 
“Have you been using suppressive therapy? How 
often do you use it?” 
Support groups  “Would you be interested in attending a herpes 
support group? Why or why not?” 
Table 2: 
Table 2: Demographic Characteristics by Recruitment Location 
Community 
Court 
N=13 
N (%) 
STD Clinic 
N=12 
N (%) 
Sig. 
Race 
African American 
White 
American Indian 
7 (54%) 
5 (38%) 
1 (8%) 
8 (67%) 
4 (33%) 
0 (0%) 
.57 
Age 
18-39 years 
40 years and older 
7 (54%) 
6 (46%) 
6 (50%) 
6 (50%) 
.85 
Homeless 3 (23%) 0 (0%) .08 
History of transactional sex 5 (38%) 0 (0%) .02 
Employment 2 (15%) 7 (58%) .03 
Educational Attainment 
High School or less 
Some college or higher 
10 (77%) 
3 (23%) 
4 (33%) 
8 (67%) 
.03 
Symptoms 
Symptomatic 
Asymptomatic 
6 (46%) 
7 (54%) 
4 (33%) 
8 (67%) 
.51 
